RHEINFELDEN, Switzerland, 27.11.2020 – Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, is pleased to announce that it has acquired the rights to DIFICLIRTM (fidaxomicin) from Astellas Pharma Europe Ltd. (“Astellas Europe”) which is subsidiary of Astellas Pharma Inc. (“Astellas”). Under the terms of the agreement, Tillotts will pay EUR 109 million to acquire the product rights from Astellas Europe in the following regions: Europe, Middle East, Africa and selected Commonwealth of Independent States (CIS). Since February 2011, DIFICLIRTM has been licensed by Astellas from Merck & Co., Inc. Kenilworth, N.J., U.S.A., known as MSD outside the U.S. and Canada (“Merck”).
DIFICLIRTM (fidaxomicin) is a narrow-spectrum macrocyclic anti-bacterial agent available as film-coated tablets and granules. It is indicated for the treatment of Clostridioides difficile infections (CDI), also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients with a body weight of at least 12.5 kg. CDI is an infection caused by the toxins of the spore-forming bacterium Clostridioides difficile, estimated to affect more than one hundred thousand people in Europe per year. Symptoms vary, but often include diarrhoea stomach pain and fever.
“I am extremely pleased to acquire the EU rights for DIFICLIRTM. Not only does it have great synergies with our existing GI-portfolio, it is also an important strategic agreement, as it will allow us to expand our presence and open additional affiliates in Europe. We are very excited about this transaction, and I would like to thank Astellas for this collaboration and making the transition straight forward,” CEO of Tillotts Pharma, Thomas A. Tóth von Kiskér, says.
COO of Tillotts Pharma, Mattias Norrman, continues, “CDI is a very serious, life threatening condition that can impact vulnerable populations such as the elderly, cancer patients and people with weak immune systems. DIFICLIRTM offers a range of formulations that can demonstrate significant benefit for a wide range of patients suffering from CDI. Using DIFICLIRTM to treat patients at high risk can reduce the risk of reoccurrence, which improves the chances of positive outcomes. Ultimately, this may help to eliminate additional costs associated with treating CDI.”
With the acquisition of DIFICLIRTM, Tillotts reaffirms its commitment to patients by providing treatments for a wide range of disorders of the GI tract, while delivering value to shareholders by expanding and diversifying the company’s portfolio. The agreement includes all trademarks and relevant IP assets, marketing authorisations, relevant contracts with third parties (to the extent solely dedicated to the product and assignable, including manufacturing) and inventory. The transaction does not include the transfer of any Astellas employees or facilities.
Um die Pressemitteilung auf Deutsch zu lesen, klicken Sie hier
Pour lire le communiqué de presse en français cliquez ici
Per leggere il comunicato stampa in italiano clicca qui
For more information, contact:
Tillotts Pharma AG
Julie Delin Fosdal
Senior Manager Corporate Communications
Phone: +41 61 935 2761
DIFICLIRTM is a macrocyclic anti-bacterial agent. It is formulated as film-coated tablets and granules for suspension both for oral route of administration. The tablets are indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg. The granules for oral suspension are indicated in CDI in adults and paediatric patients from birth to < 18 years of age. DIFICLIRTM acts by inhibiting the bacterial enzyme RNA polymerase, resulting in rapid killing of C. difficile. It eradicates C. difficile selectively with minimal disruption to the normal intestinal flora.
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD as well as in-licensed products, in around 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.
All trademarks used or mentioned in this release are protected by law. Tillotts’ trademarks include Asacol®, Asacol 1600 mg®, Octasa®, Fivasa®, Lixacol®, Asacolon®, Yaldigo®, Entocort®, Entocir®, Entocord®, Budecol®, Zentacort®, Colpermin®, VistaPrep® and are either registered or applied for in up to 70 countries. Asacol® is a registered trademark held or licensed by Actavis in the United States, Canada, and the United Kingdom. Asacol® is a registered trademark in Italy by Giuliani and in Switzerland by Sanofi. Colpermin® is a registered trademark of Johnson & Johnson in the United Kingdom and Ireland. Upon the closing of the transaction, DIFICLIRTM will be a trademark of Tillotts Pharma in the following countries: France, Germany, United Kingdom, Spain, Italy, Netherlands, Belgium, Ireland, Greece, Czech Republic, Switzerland, Slovakia, Croatia, Slovenia, Hungary, Romania, Austria, Poland, Portugal, Denmark, Finland, Norway, Sweden, South Africa, Israel, Lebanon, Saudi Arabia and Kuwait.
Copyright © 2020 Tillotts Pharma AG. All rights reserved.
For more information, please visit www.tillotts.com
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria please visit www.zeria.co.jp.